Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Conor Medsystems  (Stock symbol: CONR ) Acquired by JohnsonAndJohnson (2006 $ 1,400,000,000 )

1003 Hamilton Court
Menlo Park, CA 94025
USA
650 614 4100
Website Company Summary Management Team
Management

Technology: Stephen H. Diaz (2003)
Sales/Marketing: David Rardin
General Counsel/Legal: Lena Vinitskaya
Not listed on the website: (May no longer be at the company) Thomas Brooks*
Board

Outside board: (May no longer be on the board) Steven Gerber (Wedbush Morgan Securities Director of Research) John N. Shanley (Conor Technologies Founder) David M. Clapper (Novacept CEO) John H. Friedman (Easton Capital Partners) George Milne (Radius Ventures);  David B. Musket (ProMed Partners);  Carl J. Simpson (Versant Ventures Partner)
Advisory board: Alexandre Abizaid (Institute Dante Pazzanese of Cardiology);  Raoul Bonan (Montreal Heart Institute);  Antonio Colombo (Emo Centro Cuore Columbus);  Keith Dawkins (Southampton University Hospital);  Elazer Edelman (Harvard-MIT Biomedical Engineering Center);  Peter Fitzgerald (Stanford University Medical Center) Dean Kereiakes (The Ohio Heart Health Center);  Mitch Krucoff (Duke University Medical Center);  Martin Leon (Columbia University);  Jeffrey Moses (Columbia University);  Kinam Park (Purdue University);  Gregg Stone (Columbia University) Paul Terstein (Scripps Clinic);  Stefan Verheye (AZ Middelheim Hospital)
Company

Business description: Conor Medsystems current efforts are focused on bringing to market a drug-eluting vascular stent that represents a next generation sophistication in design and function over existing coated stents. The Conor MedStent’s proprietary technology presents expanded therapeutic opportunities for coronary and peripheral vascular disease. Nonvascular applications including Oncology are being reviewed as well. Conor’s technology is based on targeted and controlled drug eluting platforms. By delivering drugs during a specified release period directly to a target site, the stent platform provides multiple treatment options and flexibility.
Partners include: St. Jude Medical;  Biotronik
Capital

Rounds: 3
Recent Fundings: Aug 2004   Oct 2003
Capital raised: 78.0M
Last Round: 40.0M
Ownership: Acquired by JohnsonAndJohnson (2006 $ 1,400,000,000 )
Stock Symbol: CONR

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2006
Sector: Medical
Year Founded: 1999
Headcount: 51-75 as of Dec 2004
Rounds: 3
Recent Fundings: Aug 2004   Oct 2003
Capital Raised: 78.0M
Last Round: 40.0M
Ownership: Acquired by JohnsonAndJohnson (2006 $ 1,400,000,000 )
Stock Symbol: CONR